ETF Evaluator:
T. Rowe Price Biotech ETF (TDNA)
Follow This ETF
(as of Oct 13)
Best Performing in Health Over the Last Year
| 95.2% | ARK Genomic Revolution ETF (ARKG) |
| 83.2% | Global X Genomics & Biotechnology ETF (GNOM) |
| 81.0% | iShares Genomics Immnlgy & Hlthcr ETF (IDNA) |
| 71.3% | Virtus LifeSci Biotech Clinical Trls ETF (BBC) |
| 58.1% | State Street® SPDR® S&P® Biotech ETF (XBI) |
Risk
Index
Risk
Index
ETF Details
T. Rowe Price Biotech ETF Overview
T. Rowe Price Biotech ETF (TDNA) is an actively managed Sector Equity Health exchange-traded fund (ETF). T. Rowe Price launched the ETF in 2026.
The investment seeks to provide long-term capital appreciation.
The fund normally invests at least 80% of its net assets (plus any borrowings for investment purposes) in the securities of biotechnology companies. It defines biotechnology companies as companies engaged in health care innovations, such as developing new and effective therapies to treat and cure disease through the use of living cells. The fund references the MSCI GICS (Global Industry Classification Standard) biotechnology and pharmaceuticals industries to identify such companies. The fund is non-diversified.
About T. Rowe Price Biotech ETF (TDNA)
There are 1 members of the management team with an average tenure of 0.04 years: John Hall (2026). Management tenure is more important for actively managed ETFs than passive index ETFs.
T. Rowe Price Biotech ETF has 87 securities in its portfolio. The top 10 holdings constitute 27.8% of the ETF’s assets. The ETF meets the SEC requirement of being classified as a nondiversified fund. The ETF is considered to have an ESG focus with its investment selection and management.
T. Rowe Price Biotech ETF is part of the Equity global asset class and is within the Sector Equity ETF group. T. Rowe Price Biotech ETF has 2.4% of its portfolio invested in foreign issues. The overall assets allocated to domestic stock is 96.3% There is 2.4% allocated to foreign stock, and 0.0% is allocated to preferred stocks. The bond allocation as a percentage of total assets is 0.0% (0.0% domestic bond, 0.0% foreign bond and 0.0% convertible bond). T. Rowe Price Biotech ETF has 0.0% of the portfolio in cash.
Assets Under Management
The fund has $10 million in total assets, which is below the $1 billion average for the Health category. Normally, lower assets under management translates to higher average expense ratios, and greater total assets are desired. However, for some investment categories, such as small-cap investing, it may be difficult for the manager to fully employ the desired active strategy if assets grow too large or too quickly.
TDNA Performance and Fees
The expense ratio measures how much of a fund’s assets are used for administrative expenses and operating expenses, including adviser fees and fees for the transfer agent and custodial services. The T. Rowe Price Biotech ETF expense ratio is average compared to funds in the Health category. T. Rowe Price Biotech ETF has an expense ratio of 0.55%, which is 7% higher than its category average, making the fund expense ratio grade a C. While it is difficult to predict returns, it is known that high annual expense ratios reduce your rate of return, and excessive fees are difficult to overcome. Active management normally comes with higher expense ratios than passive index management. Certain investment categories such as small company and foreign also normally have higher expense ratios. It is best to compare fund expense ratios against the category averages for meaningful assessments.
High portfolio turnover can translate to higher expenses and lower aftertax returns. T. Rowe Price Biotech ETF has a portfolio turnover rate of 0%, which indicates that it holds its assets around /years. By way of comparison, the average portfolio turnover is 47% for the Health category.
Recently, in the month of September 2026, T. Rowe Price Biotech ETF returned 0.0%, which earned it a grade of NA, as the Health category had an average return of -1.4%. The letter grades of A, B, C, D and F are based upon relative rankings within the investment category. A grade of A, for example, would indicate that the return is in the highest 20% for that time period compared to all ETFs in that category.
T. Rowe Price Biotech ETF has a trailing yield of 0.00%, which is below the 1.17% category average.
The fund normally distributes its income annually and its capital gains annually.
It’s natural to seek the best-performing investments, but you must consider the relationship between risk and return and the impact of costs and taxes on your realized returns.
For more ETF grades, analysis and screening tools to help your investment discovery, join AAII for a $2, full-access trial. Learn more here: https://invest.aaii.com/membership.
Otherwise, for more information about T. Rowe Price Biotech ETF, including its riskiness, submit your email to unlock the rest of the article.
Gain access to exclusive AAII member-only content.
TDNA Trailing NAV Total Returns Data as of 9/30/26
| Last Month |
Last Quarter |
Ann'l. 1Yr |
Ann'l. 3Yr |
Ann'l. 5Yr |
Ann'l. 10Yr |
|
| TDNA Return (NAV) | na | na | na | na | na | na |
| TDNA Return (Price) | na | na | na | na | na | na |
| NAV +/- Price Return | na | na | na | na | na | na |
| Health Avg | -1.4% | 5.3% | 31.4% | 16.5% | 3.5% | 9.2% |
| TDNA Grade (NAV) | na | na | na | na | na | na |
| +/- Category (NAV) | na | na | na | na | na | na |
| TDNA Tax-Cost Ratio | na | na | na | na | na | na |
TDNA Annual NAV Total ReturnsData as of 9/30/26
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| TDNA Return (NAV) | na | na | na | na | na | na | na | na | na | na | na |
| TDNA Return (Price) | na | na | na | na | na | na | na | na | na | na | na |
| NAV +/- Price Ret | na | na | na | na | na | na | na | na | na | na | na |
| Health Avg | 16.2% | 21.8% | 0.1% | 2.2% | -16.3% | 4.3% | 30.5% | 25.4% | -1.5% | 26.5% | -10.2% |
| TDNA Grade (NAV) | na | na | na | na | na | na | na | na | na | na | na |
| +/- Category | na | na | na | na | na | na | na | na | na | na | na |
| Risk Measures | |
| Beta: | na |
| R-Squared: | na |
| Standard Deviation: | na |
| Category Risk Index: | na |
| Category Risk Rating: | |
| Total Risk Index: | na |
| Total Risk Rating: | |
| Portfolio Characteristics | |
| Yield: | -- |
| Total Assets: | $ 10 Mil |
| Share Class Assets: | $ 10 Mil |
| Turnover: | na |
| Expense Ratio: | 0.55% |
| Index Fund: | No |
| Index Tracked: | N/A |
| Index Weighting: | 100% |
| Leveraged: | No |
| Socially Responsible Fund: | Yes |
| Capital Gains Distribution Frequency: | Annually |
| Income Distribution Frequency: | Annually |
Management Team
| Number of Managers: 1 | |||
| Longest Tenure: 0.0 years | |||
| Average Tenure: 0.0 years | |||
| Managers (Year): Hall John (2026) | |||
Portfolio Composition (as of 9/30/26)
| # of Holdings: | 87 |
| % in Top 10 Holdings: | 27.8% |
| Fund is Non-Diversified: | Yes |
| % in Foreign Issues: | 2.4% |
Portfolio Allocation |
|
| Domestic Stock: | 96.3% |
| Foreign Stock: | 2.4% |
| Preferred Stock: | 0.0% |
| Domestic Bond: | 0.0% |
| Foreign Bond: | 0.0% |
| Convertible Bond: | 0.0% |
| Other: | 1.3% |
| Cash: | 0.0% |
Purchase Information
| Legal Structure: | Open Ended Investment Company |
| Fund Family: | T. Rowe Price |
| Phone Number: | 800-638-5660 |
| Website: | |
| Inception Date: | September 16, 2026 |
Expenses and Fees
| Expense Ratio (%): | 0.55% (Rating: Avg) |
| Category Average Expense Ratio (%): | 0.51% |
